82 completed, 14 unknown, 10 terminated, 4 withdrawn. 114 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 114 | Completed 82, Unknown 14, Terminated 10, Withdrawn 4, Recruiting 3, Active not recruiting 1 |
| Phase 2 | 7 | Completed 6, Recruiting 1 |
Follow Menstruation Disturbances: new trials by email Literature Review of Menstruation Disturbances trials Research Report on Menstruation Disturbances
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia KLH-2109+ Leurprorelin acetate Placebo, KLH-2109 Placebo + Leurprorelin acetate - Menorrhagia, Uterine Fibroids | Phase 3 | Recruiting | JW Pharmaceutical | 254 | 2026-02-03 | 2026-05-01 |
| Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 120 | 2024-01-15 | 2026-02-02 |
| Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea Vitex agnus-castus BNO 1095 (20 mg), Placebo - Primary Dysmenorrhea | Phase 3 | Completed | Bionorica SE | 335 | 2023-12-12 | 2025-07-28 |
| Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. BG2109, Placebo for BG2109, Placebo for add-back therapy - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Unknown | Bio Genuine (Shanghai) Biotech Co., Ltd. | 312 | 2022-12-16 | 2023-03-21 |
| Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Cramp Bites by Aunt Flo's Kitchen - Dysmenorrhea Primary, Dysmenorrhea | Phase 2 / Phase 3 | Completed | Cornell University | 12 | 2022-07-21 | 2024-04-12 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain Elagolix, Placebo, Combined Oral Contraceptive - Endometriosis | Phase 3 | Active not recruiting | AbbVie | 800 | 2020-08-10 | 2026-06-12 |
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 30 | 2020-03-23 | 2025-04-02 |
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 356 | 2020-03-05 | 2025-04-02 |
| Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 486 | 2019-06-13 | 2025-04-02 |
| A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 85 | 2019-05-23 | 2025-04-02 |
| Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women Autologous PRP intra ovarian infusion, Autologous PFP intra ovarian infusion - Infertility, Female, Anovulatory Infertility | Phase 2 / Phase 3 | Recruiting | Genesis Athens Clinic | 100 | 2019-05-21 | 2026-07-08 |
| Minimize Menorrhagia in Women With Von Willebrand Disease recombinant von Willebrand factor, tranexamic acid - Von Willebrand Diseases | Phase 3 | Terminated | Margaret Ragni | 39 | 2019-02-07 | 2024-07-01 |
| Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding Levonorgestrel 52 mg intrauterine system - Menorrhagia | Phase 3 | Completed | Medicines360 | 105 | 2019-01-17 | 2024-05-14 |
| Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss Librata - Menorrhagia, Heavy Menstrual Bleeding | Phase 3 | Unknown | LiNA Medical | 200 | 2019-01-01 | 2018-11-07 |
| Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix - Uterine Leiomyoma, Uterine Fibroids | Phase 3 | Completed | Myovant Sciences GmbH | 229 | 2018-10-16 | 2024-06-25 |
| SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain Relugolix, Estradiol/norethindrone acetate - Endometriosis | Phase 3 | Completed | Myovant Sciences GmbH | 802 | 2018-05-22 | 2023-08-08 |
| A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding Vilaprisan (BAY1002670) - Uterine Fibroids and Heavy Menstrual Bleeding | Phase 3 | Terminated | Bayer | 153 | 2018-03-30 | 2022-07-08 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 103 | 2018-01-24 | 2022-06-30 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 93 | 2018-01-17 | 2023-05-03 |
| A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain elagolix, estradiol/norethindrone acetate (E2/NETA) - Endometriosis | Phase 3 | Terminated | AbbVie | 11 | 2017-12-27 | 2019-11-27 |
Showing 20 of 114. Sign in to see all of them.
Menorrhagia (44) · Dysmenorrhea (39) · Leiomyoma (23) · Endometriosis (16) · Premenstrual Syndrome (16) · Metrorrhagia (8) · Amenorrhea (7) · Dyspareunia (7) · Polycystic Ovary Syndrome (7) · Uterine Hemorrhage (7) · Premenstrual Dysphoric Disorder (5) · Constipation (4) · Bone Diseases, Metabolic (3) · Headache (3)
Pathologic Processes (114) · Pathological Conditions, Signs and Symptoms (114) · Female Urogenital Diseases (68) · Female Urogenital Diseases and Pregnancy Complications (68) · Genital Diseases (68) · Genital Diseases, Female (68) · Urogenital Diseases (68) · Hemorrhage (44) · Uterine Diseases (44) · Signs and Symptoms (43) · Neurologic Manifestations (42) · Pain (39) · Uterine Hemorrhage (37) · Pelvic Pain (36)
elagolix (11) · estradiol, norethindrone drug combination (11) · Estradiol (9) · relugolix (8) · Levonorgestrel (7) · Tranexamic Acid (6) · asoprisnil (6) · linzagolix (6) · Ethinyl Estradiol-Norgestrel Combination (5) · Norethindrone Acetate (5) · Medroxyprogesterone Acetate (4) · Progesterone (4) · Contraceptives, Oral, Combined (3) · Ethinyl Estradiol (3) · Fluoxetine (3)
Bayer (12) · AbbVie (10) · Myovant Sciences GmbH (7) · Abbott (6) · Nobelpharma (6) · Ferring Pharmaceuticals (4) · Kissei Pharmaceutical Co., Ltd. (4) · Bionorica SE (3) · Cairo University (3) · Massachusetts General Hospital (3) · Organon and Co (3) · University of Rochester (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Assiut University (2) · Duramed Research (2)
United States (49) · Canada (15) · Czechia (13) · Poland (12) · Brazil (10) · Hungary (8) · Chile (7) · Puerto Rico (7) · South Africa (7) · Bulgaria (6) · Egypt (6) · Romania (6) · Ukraine (6) · China (5) · Italy (5)
Naoki Terakawa, M.D.,Ph.D. (5) · Dawn-Marie Walker, PhD (2) · ObsEva SA (2) · Abdelgany M Hassan, Lecturer (1) · Agni Pantou, MD (1) · Alexandre Frederico, PI (1)
PMID 34878624, PMID 29476499, PMID 32621325, PMID 32945631, PMID 33650259, PMID 33963686, PMID 37523477, PMID 36357960, PMID 37477173, PMID 37863160, PMID 19546766, PMID 20353434, PMID 21043553, PMID 21521204, PMID 23188490, PMID 24579886, PMID 28525302, PMID 30724096, PMID 30865281, PMID 30992150, PMID 31069056, PMID 31227284, PMID 31654294, PMID 31971678, PMID 32769633, PMID 33066973, PMID 33564263, PMID 33596357, PMID 34134684, PMID 34553161, PMID 34582715, PMID 35415708, PMID 35675604, PMID 35717987, PMID 36116480, PMID 37183454, PMID 37283994, PMID 37982388, PMID 39381651, PMID 39466126, PMID 40326221, PMID 40543832, PMID 10457868, PMID 12906905, PMID 15547547, PMID 16880310, PMID 17671809, PMID 18055721, PMID 18517289, PMID 18567277
2017 (5), 2016 (3), 2015 (2), 2018 (1), 2023 (1), R01DK062249 (1), R01HD060827 (1), U01HL133815 (1)